Company intelligence / Profile preview

Desupervised

Ownership: Private
Development stage: Preclinical

Overview

Desupervised develops advanced artificial intelligence platforms that enable faster, more reliable small molecule drug discovery. Their proprietary Bayesian deep learning models quantify uncertainty for better prediction of novel molecular structures. Through partnerships like the one with Red Glead Discovery, their AId tool aims to democratize access to robust AI-driven workflows in pharmaceutical R&D. No direct clinical results are reported as they provide enabling technology rather than develop drugs themselves.

Therapeutic areas: Other
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

Red Glead Discovery AB

Beyond the preview

Go deeper on Desupervised.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Desupervised.

Explore the full profile